Ipca Labs Share Price Jump 8% After Strong Q2 And H1 FY26 Results

Mumbai, November 14, 2025 – Ipca Laboratories has announced its financial performance for the Q2 FY26 and H1 FY26. The company’s share price has gained 8.25% as of 2:05 PM.

Q2 FY26 Performance: Broad-Based Growth

Standalone Q2 FY26 Highlights

The company’s revenue from operations was recorded at Rs. 1930 crore, which is up 7% from Rs. 1810 crore. The company’s export income was recorded at Rs. 813 crore, which is a 7% increase. The company’s EBITDA came in at Rs. 491.47 crore. This is a 19% surge from 414.48 crore in the corresponding period last year. The company’s net profit was recorded at Rs. 304.74 crore, which is a 25% increase. Net profit rose 25 percent to ₹304.74 crore.

The company’s EPS was increased to Rs. 12.01 from Rs. 9.62, which is a 25% increase. The company’s EBITDA margin improved to 25.46% from the 22.89% recorded in the corresponding period last year.

Consolidated Q2 FY26 Highlights

The company’s consolidated revenue for the quarter was recorded at Rs. 2,556.50 crore, which is a 9% increase. The company’s EBITDA rose to Rs. 554.31 crore, which is a 23% increase. The company’s net profit was recorded at Rs. 282.57 crore. This is a 23% increase from the corresponding period last year. The company’s EPS before the exceptional items, was at Rs. 12.35, which is a 36% increase.

H1 FY26 Performance: Steady Growth Momentum

Standalone H1 FY26

In H1 FY26, on a standalone basis, the company’s revenue was recorded at Rs. 3,677 crore, representing a 9% increase. The company’s export income was reported at Rs. 1513.41 crore, which is a 12% increase. The company’s EBITDA was recorded at 907.51 crore, which is a 19% increase. The company’s net profit was recorded at Rs. 566.78 crore, which is a 26% surge from the corresponding period last year. The company’s EBITDA stood at Rs. 22.34. This is a 26% surge.

Consolidated H1 FY26

The company’s consolidated revenue for the period H1 FY26 was recorded at Rs. 4,865.35 crore. This is a 9 percentage surge. EBITDA was recorded at Rs. 978.89 crore. This is a 17% surge. The company’s net profit was recorded at Rs. 515.78 crore. This is a 22% surge. The company’s EPS was recorded at Rs. 21.54. This is a 30% surge.

Share Price Update

The share price of Ipca Laboratories opened at Rs.1309.70, hit a high of Rs.1414 and a low of Rs.1305. In the last year, the company has dipped 7.72%, down 16.24% in the year-to-date, gained 8.57% in the past month, and up 8.81% in the previous 5 days.

REF: https://nsearchives.nseindia.com/corporate/IPCALAB_13112025134129_IpcaQ2H1FY26ResultsandPressRelease.pdf

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations